Astec LifeSciences share price, P/E, ROE & financials

Astec LifeSciences (ASTEC) is loss-making over the last 12 months, losing ₹80 Cr, so a P/E ratio does not apply. Its share price on 6 Nov 2026 was ₹559.85, 41% below its 52-week high. Sales fell 11% a year over 3 years. Debt is 0.99× equity. It is a small-cap company with a market cap of ₹1,247 Cr, ranked 27th of 72 Agricultural Inputs companies by market cap; the shares fell 15% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year

Open: ₹560.00
Day high: ₹563.55
Day low: ₹552.00
Prev. close: ₹561.25
Volume: 15.4K

Health check

1 good · 5 to check

ReturnsAhead
−15.4% over a year, better than 5 of 7 peers.
Price tagLoss-making
Earnings were negative over the last 12 months.
GrowthShrinking
Sales −10.8% a year over 3 years.
ProfitabilityNegative
ROCE -10.6% vs peer median 20.9%.
Balance sheetStretched
Debt 0.99× equity, operating profit doesn’t cover interest, Piotroski 5 of 9.
Red flags5 to check
Loss-making over the last twelve months.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Agricultural Inputs

71 listed peers. Screen the industry

Small cap

₹1,247 Cr, #27 of 72 in its industry by size.

Defensive

Beta 0.28 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Sep 2026: sales ₹439 Cr · profit ₹−80 Cr

Market cap: ₹1,247 Cr; Small cap
P/E: n/a; Industry 14.4
Price to book: 3.73; Peers 4.28
Dividend yield: 0.00%
ROE: −21.2%; Peers 16.2%
ROCE: −10.6%; Peers 20.9%
Debt to equity: 0.99; Debt ₹331 Cr
EPS (TTM): −₹35.71; Face value ₹10
OPM (TTM): −2.0%; Net margin −18.1%
Sales growth: −2.3%; Latest quarter vs a year ago
Profit growth: n/a; Year-ago quarter not reported
Price to sales: 2.84; EV/EBITDA −195.5

Risks to check

Loss-making over the last twelve months.
Return on equity is low at −21.2%.
Quarterly sales down 2.3% on a year ago.
41% below its 52-week high.
Interest coverage of only −0.1×.

No standout strengths in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Astec LifeSciences

Astec LifeSciences Limited, together with its subsidiaries, manufactures and sells agrochemical active ingredients and pharmaceutical intermediates in India. The company provides triazole fungicides for use in field crops; foliar treatment for the control of scab, powdery mildew, shot-hole, blossom blight, and rust; seed treatment for the control of seed and soil-borne diseases in cotton and maize, as well as grains, such as barley, rice, and wheat;…

Headquarters: Mumbai
Employees: 471
Sector: Basic Materials
ISIN: INE563J01010
Website: godrejastec.com

Price range

52 weeks

₹513.40₹941.75

Today

₹552.00₹563.55

Avg volume (3M): 2.4 L
1-year return: minus 15.4%
From 52-week high: minus 40.6%

Peers · Agricultural Inputs

Capital-heavy industry columns

Compare with peers Screen the whole industry

Company
COROMANDELCoromandel International	1,824.00	minus 4.00%	53,724	34.5	17.0	20.9%	9.4%	0.11	10.2%	minus 12.4%
FACTFertilisers and Chemicals Travancore	750.25	minus 1.24%	48,547	–	703.5	14.2%	0.0%	2.95	0.0%	minus 15.3%
UPLUPL	534.90	plus 1.60%	45,214	23.9	6.0	9.9%	20.0%	0.83	−1.2%	minus 28.0%
PIINDPI Industries	1,735.00	minus 1.98%	26,321	30.0	13.1	14.7%	24.2%	0.03	1.1%	minus 51.9%
SUMICHEMSumitomo Chemical India	328.95	plus 0.34%	16,419	29.4	21.0	21.0%	20.3%	0.02	−2.6%	minus 34.4%
CHAMBLFERTChambal Fertilizers & Chemicals	384.70	minus 0.91%	15,413	8.1	5.7	21.8%	13.7%	0.16	−9.2%	minus 19.4%
BAYERCROPBayer Cropscience	3,316.30	plus 0.48%	14,904	20.0	15.4	27.9%	16.0%	0.03	3.6%	minus 31.7%
ASTECAstec LifeSciences	559.85	minus 0.25%	1,247	–	–	−10.6%	−1.7%	0.99	−10.8%	minus 15.4%
Median of 7 peers	–	−0.91%	26,321	26.6	15.4	20.9%	16.0%	0.11	0.0%	−28.0%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Dec 25	Mar 26	Jun 26	Sep 26
91.1	125	159	83.6	72
102	122	149	84.2	91.8
−11	2.7	9.2	−0.7	−19.8
−12.1%	2.2%	5.8%	−0.8%	−27.5%
0.5	2.1	2.6	0.7	0.6
11	7.2	7.9	7.7	7.1
11.5	11.2	11.8	11.1	11.2
–	−2.1	–	–	–
−33	−15.7	−7.9	−18.7	−37.4
0.0%	−0.1%	1.9%	0.2%	0.1%
−33	−15.7	−7.8	−18.7	−37.4
-16.85	-7.04	-3.48	-8.40	-16.79

Sep 25 not reported by the data source.

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: −10.8%
ROE: −21.2%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
628	458	378	446
–	minus 27.1%	minus 17.4%	+17.9%
551	463	444	450
77.2	−5.3	−65.6	−4.5
12.3%	−1.2%	−17.3%	−1.0%
12	4.8	1.9	3.1
20.2	24.9	36.3	34.1
33.7	36.3	43.7	44.9
−0.4	−0.1	2.6	−0.6
34.9	−61.7	−141	−81
26.8%	24.1%	4.5%	0.2%
25.6	−46.9	−135	−80.9
12.94	-23.75	-68.19	-37.79

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
19.6	19.6	19.6	22.3
400	350	215	368
341	494	555	449
219	112	92.1	103
979	975	881	942
441	532	498	455
124	149	1.1	1.2
0	0	0	0
0.7	1.6	0.9	10.5
414	293	382	476
979	975	881	942

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
74.7	10.2	−8.4	−80.7
−113	−135	−15.2	−4.3
37.8	125	23.7	94.5
−0.1	−0	0.1	9.5
−117	−135	−21.8	−5.5
−42.6	−125	−30.2	−86.2
−2.9	−2.9	–	–

Shareholding pattern

Source: NSE filings

72.0%

promoters

Promoters71.96%
Public28.04%
As of 30 Sep 2026

Quarter	Promoters	Public	Promoter change
30 Sep 2026	71.96%	28.04%	0.00
30 Jun 2026	71.96%	28.04%	minus 0.01
31 Mar 2026	71.97%	28.03%	0.00
31 Dec 2025	71.97%	28.03%	minus 0.45
30 Sep 2025	72.42%	27.58%	–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you